Stifel Nicolaus started coverage on shares of Celgene Corporation (NASDAQ:CELG) in a research report sent to investors on Friday morning, Marketbeat reports. The brokerage issued a buy rating and a $155.00 price objective on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Jefferies Group LLC set a $154.00 price objective on Celgene Corporation and gave the company a buy rating in a research report on Saturday, May 13th. Vetr downgraded Celgene Corporation from a strong-buy rating to a buy rating and set a $132.90 price objective for the company. in a research report on Thursday, May 11th. Cann reiterated a buy rating and issued a $148.00 price objective on shares of Celgene Corporation in a research report on Tuesday, April 4th. BTIG Research reiterated a buy rating and issued a $138.00 price objective on shares of Celgene Corporation in a research report on Monday, May 1st. Finally, Cantor Fitzgerald set a $159.00 price objective on Celgene Corporation and gave the company a buy rating in a research report on Thursday, April 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have issued a buy rating to the company’s stock. Celgene Corporation has a consensus rating of Buy and a consensus price target of $146.02.

Celgene Corporation (NASDAQ:CELG) traded up 0.07% during mid-day trading on Friday, reaching $135.51. 228,155 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $131.55 and a 200-day moving average of $123.19. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The stock has a market cap of $106.02 billion, a price-to-earnings ratio of 41.97 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the previous year, the company posted $1.44 earnings per share. The business’s revenue was up 18.7% on a year-over-year basis. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/celgene-corporation-nasdaqcelg-coverage-initiated-at-stifel-nicolaus/1465411.html.

In other news, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total value of $23,604,615.80. Following the transaction, the insider now directly owns 1,033,909 shares in the company, valued at $138,688,553.26. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 227,755 shares of company stock worth $30,368,142. Corporate insiders own 0.95% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Swiss National Bank increased its position in shares of Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after buying an additional 588,000 shares during the last quarter. Edge Wealth Management LLC increased its position in shares of Celgene Corporation by 10.5% in the first quarter. Edge Wealth Management LLC now owns 15,920 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,518 shares during the last quarter. Boston Partners increased its position in shares of Celgene Corporation by 0.3% in the first quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock worth $24,620,000 after buying an additional 541 shares during the last quarter. Catawba Capital Management VA increased its position in shares of Celgene Corporation by 12.0% in the first quarter. Catawba Capital Management VA now owns 2,425 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 260 shares during the last quarter. Finally, Train Babcock Advisors LLC acquired a new position in shares of Celgene Corporation during the first quarter worth about $205,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.